Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia

NCT04641299 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04641299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04641299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 28, 2020
Completion date
July 20, 2021
Enrollment
119 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidaemia